Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Curvebeam AI Ltd. ( (AU:CVB) ) has provided an announcement.
CurveBeam AI Limited reported a successful Q4 FY25 with an 18% increase in purchase orders compared to FY24, and a significant rise in customer receipts, reaching A$5.6 million. The company is advancing its HiRise™ validation with a key robotic surgical system vendor and progressing its bone mineral density module towards FDA clearance. Additionally, CurveBeam AI is finalizing a vendor financing facility to offer leasing options, supporting direct sales in key markets.
The most recent analyst rating on (AU:CVB) stock is a Buy with a A$0.18 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.
More about Curvebeam AI Ltd.
CurveBeam AI Limited is a fully integrated developer and manufacturer of specialized medical imaging equipment, specifically point-of-care CT devices, complemented by AI-enabled SaaS-based clinical assessment solutions. The company focuses on enhancing medical imaging technology and expanding its market presence in North America and Europe.
Average Trading Volume: 171,400
Technical Sentiment Signal: Sell
Current Market Cap: A$30.05M
Find detailed analytics on CVB stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money